Veracyte (VCYT) Stock Forecast & Price Target

Veracyte is supported by a highly defensible core franchise in Decipher and Afirma, with Decipher revenue rising 27% to $310.7M in FY2025 and Afirma processing about 67,700 tests in 2025, while both still show substantial penetration headroom at roughly 33% and 38% of their U.S. addressable markets. Its outlook is strengthened by best-in-class profitability and balance-sheet resilience, as adjusted EBITDA margins reached 27.56% in FY2025, gross margin hit a record 70.1%, operating cash flow was $136.3M, and the company held $439.1M in cash with no debt as of March 31, 2026. Beyond the core, Veracyte has multiple underappreciated growth options in TrueMRD, Prosigna, and Convergent Genomics, all of which leverage the same whole-transcriptome platform, existing commercial channels, and expanding reimbursement and guideline support to extend growth into 2026 and 2027.

Veracyte is exposed to a narrowing core thesis because revenue is concentrated in Decipher and Afirma, while thyroid testing is already mature and growing only low-single-digits, making slower adoption or saturation a meaningful drag on growth. Competitive pressure is intensifying as urology diagnostics gets crowded and oncology MRD pits TrueMRD against entrenched players like Natera, Guardant Health, Exact, and Personalis, with payer controls, LBMs, and reimbursement risk threatening both volume conversion and realized pricing. Meanwhile, Q1 2026 R&D expense rose 53% to $27.1M as concurrent launches strain spend, and Medicare at ~20% of FY2025 revenue plus UnitedHealthcare at ~14% heightens exposure to CMS and commercial policy changes that could compress margins.